Pharmacological Treatment of Psoriasis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (20 December 2022) | Viewed by 5990
Special Issue Editor
Special Issue Information
Dear Colleagues,
Psoriasis is a chronic inflammatory disease that affects about 3% of the general population in Western countries, although wide variations in prevalence are being reported. It can present itself at any age with no clear gender predilection. Psoriasis exhibits primarily cutaneous manifestations; however, it is accompanied by a plethora of comorbidities, including metabolic syndrome, psoriatic arthritis, and cardiovascular disease, with a serious impact on patients’ quality of life. Over the past few decades, rapid progress has been achieved in the field of therapeutics with the introduction of new targeted biological treatments which, alongside conventional drugs, have expanded our therapeutic arsenal. Recently, IL23 inhibitors and JAK inhibitors have entered the field of psoriasis/psoriatic arthritis, along with TNFα, IL17, and IL12/23 antagonists and apremilast. Psoriasis, obesity, and metabolic syndrome constitute chronic inflammatory states that participate in a vicious circle and share a degree of synergy. These conditions can affect both conventional and biologic treatment responses in psoriasis patients, suggesting that these common inflammatory paths represent rational treatment targets. Moreover, early psoriasis treatment seems to have a beneficial effect on psoriatic arthritis. In the era of personalized medicine, there are still unmet needs that need to be addressed in order to achieve freedom from disease. Apart from achieving clear skin, individualized patient needs (such as treatment of difficult areas (e.g., genitals, nails), rapid response to therapy, and management of comorbidities and psychological burden) emphasize the importance of a multidisciplinary approach in psoriasis patients.
Dr. Evangelia Papadavid
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biologics
- comorbidities
- multidisciplinary approach
- targeted treatment
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
